DK2029524T3 - Fremgangsmåde til fremstilling af 2-[4-(3- og 2-fluorbenzyloxy)benzyl-amino]propanamider - Google Patents

Fremgangsmåde til fremstilling af 2-[4-(3- og 2-fluorbenzyloxy)benzyl-amino]propanamider

Info

Publication number
DK2029524T3
DK2029524T3 DK07764601.6T DK07764601T DK2029524T3 DK 2029524 T3 DK2029524 T3 DK 2029524T3 DK 07764601 T DK07764601 T DK 07764601T DK 2029524 T3 DK2029524 T3 DK 2029524T3
Authority
DK
Denmark
Prior art keywords
propanamides
fluorobenzyloxy
benzylamino
preparation
Prior art date
Application number
DK07764601.6T
Other languages
English (en)
Inventor
Elena Barbanti
Patricia Salvati
Francesco Velardi
Luigi Bogogna
Tiziano Ruffilli
Carla Caccia
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2029524(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Application granted granted Critical
Publication of DK2029524T3 publication Critical patent/DK2029524T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07764601.6T 2006-06-19 2007-06-08 Fremgangsmåde til fremstilling af 2-[4-(3- og 2-fluorbenzyloxy)benzyl-amino]propanamider DK2029524T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19
PCT/EP2007/005105 WO2007147491A1 (en) 2006-06-19 2007-06-08 Process for the production of 2- [4 - ( 3- and 2-flu0r0benzyl0xy) benzylamin0] propan amides

Publications (1)

Publication Number Publication Date
DK2029524T3 true DK2029524T3 (da) 2015-02-23

Family

ID=37101658

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12163085.9T DK2474521T3 (da) 2006-06-19 2007-06-08 Højrene 2-[4-(3- and 2-fluorbenzyloxy)benzylamino]propanamider til anvendelse som lægemidler og farmaceutiske formuleringer dermed
DK07764601.6T DK2029524T3 (da) 2006-06-19 2007-06-08 Fremgangsmåde til fremstilling af 2-[4-(3- og 2-fluorbenzyloxy)benzyl-amino]propanamider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12163085.9T DK2474521T3 (da) 2006-06-19 2007-06-08 Højrene 2-[4-(3- and 2-fluorbenzyloxy)benzylamino]propanamider til anvendelse som lægemidler og farmaceutiske formuleringer dermed

Country Status (26)

Country Link
US (2) US8076515B2 (da)
EP (2) EP2474521B1 (da)
JP (2) JP5240476B2 (da)
KR (2) KR101410291B1 (da)
CN (2) CN103284984B (da)
AR (1) AR061510A1 (da)
AU (1) AU2007263328C1 (da)
BR (1) BRPI0712936B8 (da)
CA (1) CA2653012C (da)
CY (2) CY1115951T1 (da)
DK (2) DK2474521T3 (da)
EA (2) EA017123B1 (da)
ES (2) ES2527437T3 (da)
HR (2) HRP20150136T1 (da)
HU (1) HUE030233T2 (da)
IL (1) IL195294A (da)
LT (1) LT2474521T (da)
MX (2) MX342698B (da)
NO (2) NO342018B1 (da)
NZ (2) NZ572798A (da)
PL (2) PL2029524T3 (da)
PT (2) PT2474521T (da)
RS (2) RS53824B1 (da)
SI (2) SI2474521T1 (da)
TW (2) TWI393700B (da)
WO (1) WO2007147491A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
DK2474521T3 (da) * 2006-06-19 2016-10-31 Newron Pharm Spa Højrene 2-[4-(3- and 2-fluorbenzyloxy)benzylamino]propanamider til anvendelse som lægemidler og farmaceutiske formuleringer dermed
KR101593627B1 (ko) 2007-12-11 2016-02-11 뉴론 파마슈티칼즈 에스. 피. 에이. 고순도의 ２­［４­（３­ 또는 ２­플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
NZ602648A (en) * 2010-04-27 2014-10-31 Newron Pharm Spa Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
WO2014086704A1 (en) 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1)
US9475757B2 (en) 2013-05-03 2016-10-25 Council Of Scientific & Industrial Research Synthesis of anti-Parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN106365966A (zh) * 2015-07-24 2017-02-01 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
ES2977486T3 (es) 2019-08-06 2024-08-26 Medichem Sa Proceso para preparar safinamida
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN117923998A (zh) * 2022-10-24 2024-04-26 中国石油化工股份有限公司 苯甲醛及其衍生物的制备方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法
AU2024298771A1 (en) 2023-07-25 2026-01-22 Intas Pharmaceuticals Ltd. An orodispersible pharmaceutical solid dosage form of safinamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
NZ521870A (en) 2000-03-31 2004-08-27 Euro Celtique S Aminopyridines and their use as anticonvulsants and sodium channel blockers
SI1423168T1 (sl) 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
ES2339021T3 (es) 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20080096965A1 (en) 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
DK2474521T3 (da) * 2006-06-19 2016-10-31 Newron Pharm Spa Højrene 2-[4-(3- and 2-fluorbenzyloxy)benzylamino]propanamider til anvendelse som lægemidler og farmaceutiske formuleringer dermed
KR101593627B1 (ko) * 2007-12-11 2016-02-11 뉴론 파마슈티칼즈 에스. 피. 에이. 고순도의 ２­［４­（３­ 또는 ２­플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
CA2707646C (en) * 2007-12-19 2016-09-13 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

Also Published As

Publication number Publication date
CY1115951T1 (el) 2017-01-25
PL2474521T3 (pl) 2017-01-31
JP5795342B2 (ja) 2015-10-14
HRP20161456T1 (hr) 2016-12-16
PL2029524T3 (pl) 2015-04-30
CY1118113T1 (el) 2017-06-28
NO20171916A1 (no) 2009-01-16
LT2474521T (lt) 2016-11-25
US8278485B2 (en) 2012-10-02
EA025326B1 (ru) 2016-12-30
AU2007263328A1 (en) 2007-12-27
ES2527437T3 (es) 2015-01-26
JP2013139446A (ja) 2013-07-18
US20120157712A1 (en) 2012-06-21
CA2653012A1 (en) 2007-12-27
PT2029524E (pt) 2015-03-09
AU2007263328A2 (en) 2009-02-19
NZ595737A (en) 2013-04-26
HK1130245A1 (en) 2009-12-24
AU2007263328C1 (en) 2012-09-06
NO342644B1 (no) 2018-06-25
EP2474521A1 (en) 2012-07-11
BRPI0712936B1 (pt) 2021-02-23
CA2653012C (en) 2014-08-05
NZ572798A (en) 2011-11-25
JP2009541232A (ja) 2009-11-26
HUE030233T2 (en) 2017-04-28
CN101472880B (zh) 2013-04-24
US20090156678A1 (en) 2009-06-18
TWI393700B (zh) 2013-04-21
SI2029524T1 (sl) 2015-03-31
KR101410291B1 (ko) 2014-06-20
AR061510A1 (es) 2008-09-03
EP2474521B1 (en) 2016-08-10
NO342018B1 (no) 2018-03-12
ES2602069T3 (es) 2017-02-17
EA017123B1 (ru) 2012-10-30
KR20140027563A (ko) 2014-03-06
EP2029524B1 (en) 2014-11-26
EA201101308A1 (ru) 2012-02-28
BRPI0712936B8 (pt) 2021-05-25
CN101472880A (zh) 2009-07-01
CN103284984B (zh) 2016-08-03
NO20090231L (no) 2009-01-16
KR20090021392A (ko) 2009-03-03
PT2474521T (pt) 2016-11-10
MX2008015704A (es) 2009-01-09
BRPI0712936A2 (pt) 2012-12-18
TW200815322A (en) 2008-04-01
TWI412512B (zh) 2013-10-21
RS55464B1 (sr) 2017-04-28
DK2474521T3 (da) 2016-10-31
IL195294A (en) 2015-03-31
KR101491541B1 (ko) 2015-02-09
EP2029524A1 (en) 2009-03-04
JP5240476B2 (ja) 2013-07-17
CN103284984A (zh) 2013-09-11
US8076515B2 (en) 2011-12-13
MX342698B (es) 2016-10-10
WO2007147491A1 (en) 2007-12-27
AU2007263328B2 (en) 2012-03-22
RS53824B1 (sr) 2015-06-30
TW201313662A (zh) 2013-04-01
EA200970028A1 (ru) 2009-06-30
SI2474521T1 (sl) 2016-12-30
IL195294A0 (en) 2009-08-03
HRP20150136T1 (xx) 2015-03-13

Similar Documents

Publication Publication Date Title
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2489662T3 (da) Mellemprodukter af en ny fremgangsmåde til fremstillingen af 5-benzyliden-2-alkylimino-3-phenylthiazolidin-4-on derivater
HRP20150136T1 (xx) Postupak dobivanja 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamida
DK2178863T3 (da) Fremgangsmåde til syntetisering af anvendelige forbindelser til behandling af hepatitis C
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK2118090T3 (da) Fremgangsmåde til fremstilling af et benzimidazolderivat
DK1945271T3 (da) Fremgangsmåde til fremstilling af polymerbelagte mikropartikler
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1884507T3 (da) Fremgangsmåde til fremstilling af glycerol
DK2348064T3 (da) Fremgangsmåde til fremstilling af polyalkylenglycolderivater
DK1637610T3 (da) Fremgangsmåde til fremstilling af alkylestere
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK1968949T3 (da) Forbedret fremgangsmåde til fremstilling af salte af 4-(benzimidazolylmethylamino)-benzamider
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
EP2374799A4 (en) PROCESS FOR PREPARING 4- (1-HYDROXY-1-METHYLETHYL) -2-PROPYLIMIDAZOLE-5-CARBOXYLATE
DK2229062T3 (da) Fremgangsmåde til fremstillingen af et hydrolysat
DK2094366T3 (da) Fremgangsmåde til oprensning af sialyllactose ved chromatografi
DK2151429T3 (da) Fremgangsmåde til fremstilling af agomelatin
DK2245000T3 (da) Fremgangsmåde til fremstilling af optisk aktive alfa-aminoacetaler